News Search Results
May 29, 2025, 03:00 ET ARTHEx Biotech to Participate in the 2025 Jefferies Global Healthcare Conference
Spain, May 29, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 Jefferies
More news about: ARTHEx Biotech
May 28, 2025, 17:31 ET Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight
including Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Acasti Pharma Inc., Staten Biotechnology BV, NorthSea Therapeutics B.V., Afimmune, Rivus Pharmaceuticals, Novo Nordisk, Viking Therapeutics, Liminal BioSciences, Matinas BioPharma, Arbutus
More news about: DelveInsight Business Research, LLP
May 28, 2025, 16:05 ET Halozyme to Participate at Upcoming Investor Conferences
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
May 28, 2025, 16:02 ET Immunic, Inc. Announces Proposed Public Offering
Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
May 28, 2025, 13:00 ET Cizzle Bio Expands Global Reach with Cayman Islands Launch of Biomarker Blood Tests for Lung and Gastric Cancers
Cayman Islands, May 28, 2025 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company pioneering innovative biomarker blood tests for early detection of lung and gastric cancers, has announced an agreement with Doctors Hospital
More news about: Cizzle Bio
May 28, 2025, 12:27 ET U.S. Standardization Center of Excellence for Critical and Emerging Technologies Holds Major Workshop, Launches Website
global standardization efforts. The workshop also explored the ways ASCET can advance standards for CETs like artificial intelligence, quantum, and biotechnology, among others. The workshop included a robust agenda of: presentations and panel sessions on the introduction of
More news about: ASTM International
May 28, 2025, 12:19 ET AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B
/PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced
More news about: AusperBio Therapeutics Inc.
May 28, 2025, 10:05 ET PooPrints Partners with Ancestry to Deliver Pet Health Insights to Millions of Multifamily Units
privacy and ease of access. About PooPrints PooPrints is a service offered by BioPet Laboratories Inc., an international biotechnology company specializing in animal genomics and DNA testing. PooPrints is the original and only DNA pet waste management solution for apartments, parks,
More news about: PooPrints
May 28, 2025, 09:00 ET Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile
Calif., May 28, 2025 /PRNewswire/ -- Evommune, Inc., a clinical-stage biotechnology company developing innovative therapies for chronic inflammatory diseases, today announced positive top-line data from its Phase 2 trial of EVO756
More news about: Evommune, Inc
May 28, 2025, 08:30 ET Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
More news about: Spyre Therapeutics, Inc.
May 28, 2025, 08:30 ET Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
May 28, 2025, 08:05 ET Rigel to Present at the Jefferies Global Healthcare Conference
May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.
May 28, 2025, 08:00 ET TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drug
More news about: TransCode Therapeutics, Inc.
May 28, 2025, 08:00 ET Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone
attentions from key industry stakeholders across branding, R&D, and formulation and aligning with current hot trends such as sustainability, biotechnology, and personalized care. Meanwhile, the Inspiration Hive, as a high-end communication platform, will enable KT-939 to explore collaboration opportunities,
More news about: Kintor
May 28, 2025, 08:00 ET Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill
More news about: Intensity Therapeutics Inc.
May 28, 2025, 08:00 ET Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
asset to new markets." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®),
More news about: Formosa Pharmaceuticals Inc.,
May 28, 2025, 08:00 ET Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS
DIEGO, May 28, 2025 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company focused on developing novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including
More news about: Transposon Therapeutics
May 28, 2025, 07:00 ET Hillstar Bio Appoints Maude Tessier, Ph.D., as Chief Operating Officer and Expands Leadership Team to Advance Pipeline of Precision Immunotherapies
BOSTON, May 28, 2025 /PRNewswire/ -- Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the appointment of Maude
More news about: Hillstar Bio
May 28, 2025, 06:55 ET Grignard Reagents Market worth $6.67 billion in 2030 - Exclusive Report by MarketsandMarkets™
https://www.marketsandmarkets.com/requestsampleNew.asp?id=58405196 Pharmaceutical & biotechnology segment to record highest CAGR in Grignard reagents market during forecast period The pharmaceutical & biotechnology industry has emerged as the fastest-growing end-use industry in the Grignard reagents
More news about: MarketsandMarkets
May 28, 2025, 03:28 ET Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone
attentions from key industry stakeholders across branding, R&D, and formulation and aligning with current hot trends such as sustainability, biotechnology, and personalized care. Meanwhile, the Inspiration Hive, as a high-end communication platform, will enable KT-939 to explore collaboration opportunities,
More news about: Kintor
May 27, 2025, 16:05 ET ClearSign Technologies Corporation Announces Changes to Board of Directors
with and enabling investment into early-stage disruptive technologies for most of his career. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. Mr. DiGiandomenico currently serves as the Chief of Transactions and director of
More news about: ClearSign Technologies Corporation
May 27, 2025, 12:12 ET Global Times: Invest in China, invest in future: Foreign business leaders discuss opportunities in China
a pivotal role, he said.Currently, breakthroughs have been made in the application of innovative fields such as AI, big data, biotechnology, quantum computing, and electric vehicles, providing new opportunities for the global business community to cooperate.Hofmann,
More news about: Global Times
May 27, 2025, 11:11 ET Wound Care Market Value worth $29.57 billion by 2030 - Exclusive Report by The Research Insights
https://www.theresearchinsights.com/Ask_For_Customization?id=427 Conclusion: The wound care industry worldwide is experiencing significant changes thanks to advancements in biotechnology and personalized medicine along with digital health technology integration. Chronic wounds along with surgical site infections and traumatic injuries
More news about: The Research Insights
May 27, 2025, 10:05 ET Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer
Health, and Vyant Bio. Until February 2023, Roberts served as president and CEO of Vyant Bio, an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Throughout his distinguished career, Roberts
More news about: Life365
May 27, 2025, 10:01 ET Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America,
More news about: Meticulous Market Research Pvt. Ltd.